NDUFAB1
ENSG00000004779
Target class
Enzyme
Chromosome
16
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFAB1
- Gene name
- NADH:ubiquinone oxidoreductase subunit AB1
- Gene symbol
- NDUFAB1
- Protein name
- Acyl carrier protein, mitochondrial (ACP) (CI-SDAP) (NADH-ubiquinone oxidoreductase 9.6 kDa subunit)
- SDAP
- FASN2A
- ACP
- ACP1
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 164.48
- Tissue specificity (Gini)
- 0.188
- Tissue specificity (tau)
- 0.652
- KEGG gene identifiers
- hsa:4706
- Protein interaction confidence
- 0.912569
- Protein interaction partners
- 197
- R-HSA-611105
- R-HSA-6799198
- R-HSA-77289
- R-HSA-9857492
- R-HSA-9937383
- End position
- 23596319
- Start position
- 23581014
- Chromosome
- 16
- Strand
- Reverse
- Mitochondrion .
- Mitochondria
- PubMed 12611891
- PubMed 28892042
- Tissue specificity (tau)
- 0.652177
- Expression inequality (Gini)
- 0.188108
Expression in transcripts per million
- Heart - Atrial Appendage
- 164.48
- Heart - Left Ventricle
- 158.7
- Muscle - Skeletal
- 106.53
- Cells - EBV-transformed lymphocytes
- 104.03
- Brain - Frontal Cortex (BA9)
- 80.21
Expression in transcripts per million
- Heart - Atrial Appendage164.48
- Heart - Left Ventricle158.7
- Muscle - Skeletal106.53
- Cells - EBV-transformed lymphocytes104.03
- Brain - Frontal Cortex (BA9)80.21
- Brain - Cerebellar Hemisphere75.61
- Colon - Sigmoid72.86
- Pituitary69.42
- Colon - Transverse67.28
- Adrenal Gland65.83
- Brain - Cerebellum65.75
- Kidney - Medulla63.45
- Artery - Coronary63.19
- Esophagus - Muscularis62.19
- Artery - Tibial62.03
- Artery - Aorta61.7
- Brain - Cortex60.54
- Fallopian Tube60
- Brain - Anterior cingulate cortex (BA24)59.77
- Cells - Cultured fibroblasts59.56
- Esophagus - Gastroesophageal Junction59.25
- Brain - Hypothalamus58.58
- Brain - Nucleus accumbens (basal ganglia)57.09
- Testis56.97
- Thyroid55.94
And 29 more, listed on the interactive page.
- GO:0009249
- GO:0044571
- GO:1902775
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0099128
- GO:0005198
- GO:0005515
- GO:0140978
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor